Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
100 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-09-01
Study Completion Date
2025-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background:
Bladder and bowel dysfunction (BBD) is characterized by lower urinary tract symptoms accompanied by bowel complaints. BBD is a common condition in childhood. The present treatment strategy for BBD is a step-wise approach starting with management of bowel symptoms before initiation of standard urotherapy and further medical treatment of LUTS symptoms. This is, however, based on clinical experience and few retrospective, non-randomized studies and high-level evidence of the succession of the elements in treatment of BBD children is missing.
Our microbiome, and its role in health and disease, has gained increased focus during the past years. Studies suggest the urine and gut microbiome to be critical for maintenance of a well-functioning bladder- and bowel system. The microbiome in children is only sparsely investigated and its role in BBD is to the investigator's knowledge still unexplored.
Study 1:
Aim: To investigate if combination therapy is more effective in treating urinary incontinence in BBD children.
Materials and methods: A prospective randomized multicentre study on children with BBD (n=100) between 5-14 years and 9 months old. They are randomized to: 1) Medical treatment of bowel symptoms (n=50) or 2) Medical treatment of bowel symptoms combined with standard urotherapy.
The effect of treatment will be evaluated after 3 months. Primary endpoint: Resolution of incontinence after treatment. Secondary endpoint: Improved quality of life after successful treatment of urinary incontinence.
Study 2:
Aim: To investigate the urofecal microbiome in children with BBD
Materials and methods:
1. A cohort study to investigate, whether the urofecal microbiome can predict response to treatment and whether it changes during treatment period
2. A case control study to investigate whether the urofecal microbiome is different in children with BBD and recurrent UTI 's and children with BBD without recurrent UTI 's.
The study population consists of children with BBD included in study 1. A urine-, stool sample and a perineum swab will be collected from all participants before and after treatment. Bacterial DNA will be extracted and the microbiome will be determined.
Perspectives:
BBD is a common condition in childhood. It is associated with a considerable psychological burden and a risk of more severe physical complications.
The studies will provide basic knowledge about characteristics of the BBD patients and contribute new information about the optimal treatment of BBD children.
Bladder and bowel dysfunction (BBD) is characterized by lower urinary tract symptoms accompanied by bowel complaints. BBD is a common condition in childhood. The present treatment strategy for BBD is a step-wise approach starting with management of bowel symptoms before initiation of standard urotherapy and further medical treatment of LUTS symptoms. This is, however, based on clinical experience and few retrospective, non-randomized studies and high-level evidence of the succession of the elements in treatment of BBD children is missing.
Our microbiome, and its role in health and disease, has gained increased focus during the past years. Studies suggest the urine and gut microbiome to be critical for maintenance of a well-functioning bladder- and bowel system. The microbiome in children is only sparsely investigated and its role in BBD is to the investigator's knowledge still unexplored.
Study 1:
Aim: To investigate if combination therapy is more effective in treating urinary incontinence in BBD children.
Materials and methods: A prospective randomized multicentre study on children with BBD (n=100) between 5-14 years and 9 months old. They are randomized to: 1) Medical treatment of bowel symptoms (n=50) or 2) Medical treatment of bowel symptoms combined with standard urotherapy.
The effect of treatment will be evaluated after 3 months. Primary endpoint: Resolution of incontinence after treatment. Secondary endpoint: Improved quality of life after successful treatment of urinary incontinence.
Study 2:
Aim: To investigate the urofecal microbiome in children with BBD
Materials and methods:
1. A cohort study to investigate, whether the urofecal microbiome can predict response to treatment and whether it changes during treatment period
2. A case control study to investigate whether the urofecal microbiome is different in children with BBD and recurrent UTI 's and children with BBD without recurrent UTI 's.
The study population consists of children with BBD included in study 1. A urine-, stool sample and a perineum swab will be collected from all participants before and after treatment. Bacterial DNA will be extracted and the microbiome will be determined.
Perspectives:
BBD is a common condition in childhood. It is associated with a considerable psychological burden and a risk of more severe physical complications.
The studies will provide basic knowledge about characteristics of the BBD patients and contribute new information about the optimal treatment of BBD children.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diaphragmatic Breathing as an Adjunctive Therapy in the Management of Children With Bladder and Bowel Disorders
NCT02597764
Bladder and Bowel Disorder, Pediatric
COMPLETED
NA
Voiding Class Study for Symptom Reduction and Quality of Life in Children With LUTS
NCT05146258
Lower Urinary Tract Symptoms
COMPLETED
The Effectiveness of a Bladder Training Video for Management of Lower Urinary Tract Symptoms.
NCT01915004
Nonneurogenic Lower Urinary Tract Dysfunction
Dysfunctional Elimination Syndrome
COMPLETED
NA
Impaired Toilet Training, LUTS and Bowel Dysfunction in Children With DCD
NCT06311110
Developmental Coordination Disorder
Lower Urinary Tract Symptoms
Bowel Dysfunction
RECRUITING
Urotherapy vs. Urotherapy With Constipation Treatment for Children With Lower Urinary Tract Dysfunction
NCT02336906
Diurnal Enuresis
WITHDRAWN
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background Bladder and bowel dysfunction (BBD) is characterised by lower urinary tract symptoms (LUTS) accompanied by bowel complaints, primarily functional constipation and/or faecal incontinence. To standardise the terminology used for BBD, LUTS symptoms related to the disease have been defined by International Children's Continence Society (ICCS).
The prevalence of BBD is probably underestimated but studies suggest BBD to be present in up to 20 % of school children and to represent up to 40% of paediatric urology consults.
Embryological, anatomical and functional interactions between the rectum and urinary bladder are well known. Bladder and bowel are anatomically closely related and share innervation from the parasympathetic S2-S4 and sympathetic L1-L3 nerve roots.
Research on successful treatment of BBD is sparse, with only few retrospective, non-randomized studies, documenting that treatment of defecation problems in children with BBD enhances successful management of lower urinary tract disturbances such as daytime urinary incontinence (DUI), enuresis and urinary tract infections (UTI's). Based on this knowledge and clinical experience, the present treatment strategy for children with BBD is a step-wise approach starting with management of bowel symptoms before initiation of standard urotherapy and further medical treatment of LUTS symptoms. Standard urotherapy encompasses information and demystification of the disorder along with behavioural modification such as timed voiding, proper voiding posture, avoidance of holding manoeuvers and balanced fluid intake. Standard urotherapy is well-established as first-line treatment for children with LUTS. However, high-level evidence of the succession of the elements in treatment of BBD children is missing.
BBD is commonly associated with vesicoureteral reflux (VUR) and recurrent UTI's, which may lead to renal scarring , kidney failure and hypertension. It is a potential cause of significant physical and psychosocial burden for children and families. Therefore, optimization of treatment is critical to avoid secondary comorbidities.
Our microbiome, and its role in health and disease, has gained increased focus during the past few years.
Studies suggest the urine and gut microbiome to be critical for maintenance of a well-functioning bladder- and bowel system.
Dysbiosis is defined by the presence of unbalanced and disease-promoting composition of the microbiome. It is well-established that dysbiosis is associated with constipation in children and the condition is suspected to be involved in urological disorders such as overactive bladder, urge, incontinence and recurrent UTI's in adults. However, the composition of the urine microbiome in children is only sparsely investigated and its role in BBD and childhood UTI's is to the investigator's knowledge still unexplored.
Study 1: Does successful treatment of bowel symptoms resolve urinary incontinence in children with BBD? Aim and hypothesis Aim: To investigate if effective treatment of bowel problems resolves urinary incontinence in BBD children.
The hypothesis of the investigators is:
1. Treatment of bowel symptoms resolves urinary incontinence in BBD children.
2. It is more effective to initiate urotherapy from the beginning in combination with treatment of bowel symptoms instead of the present regime where bowel symptoms are managed before urotherapy is started.
3. Succesful treatment of urinary incontinence in children with BBD improves their quality of life.
1.2 Materials and methods A prospective multicentre randomised study on children with BBD referred to the Pediatric Incontinence and Gastroenterology outpatient clinics at the Department of Pediatrics, Aarhus University Hospital, Aalborg University Hospital and Regional Hospital Goedstrup.
Children (n=100) between 5-14 years and 9 months diagnosed with BBD at their first visit to the outpatient clinic will be included if they meet in- and exclusion criteria.
The included children will be randomised to one of the following treatments:
1. Medical treatment of bowel symptoms in accordance with the guidelines of The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) (n=50)
2. Medical treatment of bowel symptoms in accordance with the ESPGHAN guidelines combined with standard urotherapy (n=50)
At first visit to the outpatient clinic, enrolled children will undergo physical examination including neurological examination. Data on medical history will be collected including number of and time for UTI's. Participants will be asked to fill in a 48-hour flow-volume chart and in case of enuresis nocturna the chart will also include registration for 7 nights. Participants will also fill in "Toerfisk" which is a validated tool to monitor severity of urinary incontinence. Routine uroflowmetry will be performed for further evaluation of lower urinary symptoms. A urine sample will be collected for diagnosing on-going UTI and for microbiome analysis in study 3. The children will be screened for constipation in accordance with the ROME IV criteria. Rectal examination will be performed or transrectal diameter will be evaluated with point-of-care ultrasound. Stool sample and perineum swab will be collected for microbiome analysis.
The psychological burden from the children´s BBD condition will be evaluated by PinQ, a validated questionnaire used for assessment of quality of life according to the incontinence issue of the patients.
All participants will be informed about bladder and bowel function in order to demystify the disorder. Daily defecation will be induced by reconditioning to normal bowel habits through timed toilet sitting and daily administration of laxatives (e.g. PEG3350) in relevant dosage according to the ESPGHAN guidelines.
Participants randomized to combined medical treatment for bowel symptoms and urotherapy will be instructed in urotherapy in accordance with earlier description.
After 1 month of treatment the participants will be contacted by telephone to ensure compliance and for adjustment of laxative dose depending on the bowel symptoms.
The second visit in the outpatient clinic will be after 3 months of treatment. Before the consultation, the participants will be asked to fill in a second flow-volume chart as well as "Toerfisk" and PinQ questionnaires. Uroflowmetry will be repeated and a second urine sample will be collected for stix, culturing and microbiome analysis. Bowel symptoms will be evaluated using ROME IV, rectal examination and transrectal diameter and a second stool sample and perineum swab will be collected for microbiome analysis for study 3.
Data storage Data will be entered into RedCap, which is a secure web platform for building and managing online databases.
Power estimation The sample size (n=100) was calculated for each group to achieve a power of 80% for detecting a difference in proportions of 0.30 between the two groups (test - reference group) at a two sided p-value of 0.05.
Study 2: Urine, perineal and gut microbiome in children with BBD before and after treatment Aim and hypothesis To investigate the urine, perineal and gut microbiome in children with BBD before and after treatment.
The hypothesis of the investigators is that
1. Response to treatment can be predicted by the composition of the urine, perineal and gut microbiome in children with BBD.
2. The composition of the urine, perineal and gut microbiome is different in BBD children with recurrent UTI's compared to BBD children without recurrent UTI's.
3. The urine, perineal and gut microbiome in children with BBD will change when bladder and bowel symptoms successfully treated.
Materials and methods
The study is a multicentre study consisting of two elements:
1. a cohort study to investigate, whether the urine, perineal and gut microbiome can predict response to treatment and whether it changes during treatment period
2. a case control study to investigate whether the urine, perineal and gut microbiome is different in children with BBD and recurrent UTI 's and children with BBD without recurrent UTI 's.
The study population consists of children with BBD included in study 1.
Collection and analysis of samples A urine-, stool sample and a perineum swab will be collected from all participants before initiation of treatment and after 3 months of treatment as described in study 1. Bacterial DNA will be extracted and the microbiome will be determined.
Data storage Biological material will be pseudonymised and stored in a -80 degree fridge until analysis is performed.
Statistical analysis for all 3 studies Distribution and variance will be analysed by QQ plot, Shapiro-Wilks test and Bartletts test. Microbiota alpha-diversity will be addressed by ASV richness, Faith's phylogenetic diversity, Shannon diversity index, and Pielou's evenness index. Beta-diversity analysis will include principal coordinate analysis (PCoA) using Bray-Curtis dissimilarity, weighted and unweighted UniFrac. Parametric data will be compared using Student's t-test or one-way ANOVA and Tukey´s post hoc test, while non-parametric data will be compared with Kruskal-Wallis test or Mann-Whitney U-test. Chi Squared test will be used for proportions. Level of significance will be as following \*: p \<0.05, \*\*: p\<0.01 and \*\*\*: p\<0.001.
Ethics The studies will be conducted in accordance with the Declaration of Helsinki. All side effects will be handled in accordance with the actual legislation. No risk or unknown side effects are expected to urotherapy or medical treatment of bowel symptoms. No risk, side effects or discomfort is expected from collection of urine, stool and perineum samples or from uroflowmetry or transabdominal ultrasound.
Perspectives BBD is a common condition in childhood. It is associated with a considerable psychological burden and a risk of more severe physical complications.
The term BBD is recently defined and therefore only sparsely investigated. The studies will provide basic knowledge about characteristics of the BBD patients and contribute new information about the optimal treatment of BBD children.
The prevalence of BBD is probably underestimated but studies suggest BBD to be present in up to 20 % of school children and to represent up to 40% of paediatric urology consults.
Embryological, anatomical and functional interactions between the rectum and urinary bladder are well known. Bladder and bowel are anatomically closely related and share innervation from the parasympathetic S2-S4 and sympathetic L1-L3 nerve roots.
Research on successful treatment of BBD is sparse, with only few retrospective, non-randomized studies, documenting that treatment of defecation problems in children with BBD enhances successful management of lower urinary tract disturbances such as daytime urinary incontinence (DUI), enuresis and urinary tract infections (UTI's). Based on this knowledge and clinical experience, the present treatment strategy for children with BBD is a step-wise approach starting with management of bowel symptoms before initiation of standard urotherapy and further medical treatment of LUTS symptoms. Standard urotherapy encompasses information and demystification of the disorder along with behavioural modification such as timed voiding, proper voiding posture, avoidance of holding manoeuvers and balanced fluid intake. Standard urotherapy is well-established as first-line treatment for children with LUTS. However, high-level evidence of the succession of the elements in treatment of BBD children is missing.
BBD is commonly associated with vesicoureteral reflux (VUR) and recurrent UTI's, which may lead to renal scarring , kidney failure and hypertension. It is a potential cause of significant physical and psychosocial burden for children and families. Therefore, optimization of treatment is critical to avoid secondary comorbidities.
Our microbiome, and its role in health and disease, has gained increased focus during the past few years.
Studies suggest the urine and gut microbiome to be critical for maintenance of a well-functioning bladder- and bowel system.
Dysbiosis is defined by the presence of unbalanced and disease-promoting composition of the microbiome. It is well-established that dysbiosis is associated with constipation in children and the condition is suspected to be involved in urological disorders such as overactive bladder, urge, incontinence and recurrent UTI's in adults. However, the composition of the urine microbiome in children is only sparsely investigated and its role in BBD and childhood UTI's is to the investigator's knowledge still unexplored.
Study 1: Does successful treatment of bowel symptoms resolve urinary incontinence in children with BBD? Aim and hypothesis Aim: To investigate if effective treatment of bowel problems resolves urinary incontinence in BBD children.
The hypothesis of the investigators is:
1. Treatment of bowel symptoms resolves urinary incontinence in BBD children.
2. It is more effective to initiate urotherapy from the beginning in combination with treatment of bowel symptoms instead of the present regime where bowel symptoms are managed before urotherapy is started.
3. Succesful treatment of urinary incontinence in children with BBD improves their quality of life.
1.2 Materials and methods A prospective multicentre randomised study on children with BBD referred to the Pediatric Incontinence and Gastroenterology outpatient clinics at the Department of Pediatrics, Aarhus University Hospital, Aalborg University Hospital and Regional Hospital Goedstrup.
Children (n=100) between 5-14 years and 9 months diagnosed with BBD at their first visit to the outpatient clinic will be included if they meet in- and exclusion criteria.
The included children will be randomised to one of the following treatments:
1. Medical treatment of bowel symptoms in accordance with the guidelines of The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) (n=50)
2. Medical treatment of bowel symptoms in accordance with the ESPGHAN guidelines combined with standard urotherapy (n=50)
At first visit to the outpatient clinic, enrolled children will undergo physical examination including neurological examination. Data on medical history will be collected including number of and time for UTI's. Participants will be asked to fill in a 48-hour flow-volume chart and in case of enuresis nocturna the chart will also include registration for 7 nights. Participants will also fill in "Toerfisk" which is a validated tool to monitor severity of urinary incontinence. Routine uroflowmetry will be performed for further evaluation of lower urinary symptoms. A urine sample will be collected for diagnosing on-going UTI and for microbiome analysis in study 3. The children will be screened for constipation in accordance with the ROME IV criteria. Rectal examination will be performed or transrectal diameter will be evaluated with point-of-care ultrasound. Stool sample and perineum swab will be collected for microbiome analysis.
The psychological burden from the children´s BBD condition will be evaluated by PinQ, a validated questionnaire used for assessment of quality of life according to the incontinence issue of the patients.
All participants will be informed about bladder and bowel function in order to demystify the disorder. Daily defecation will be induced by reconditioning to normal bowel habits through timed toilet sitting and daily administration of laxatives (e.g. PEG3350) in relevant dosage according to the ESPGHAN guidelines.
Participants randomized to combined medical treatment for bowel symptoms and urotherapy will be instructed in urotherapy in accordance with earlier description.
After 1 month of treatment the participants will be contacted by telephone to ensure compliance and for adjustment of laxative dose depending on the bowel symptoms.
The second visit in the outpatient clinic will be after 3 months of treatment. Before the consultation, the participants will be asked to fill in a second flow-volume chart as well as "Toerfisk" and PinQ questionnaires. Uroflowmetry will be repeated and a second urine sample will be collected for stix, culturing and microbiome analysis. Bowel symptoms will be evaluated using ROME IV, rectal examination and transrectal diameter and a second stool sample and perineum swab will be collected for microbiome analysis for study 3.
Data storage Data will be entered into RedCap, which is a secure web platform for building and managing online databases.
Power estimation The sample size (n=100) was calculated for each group to achieve a power of 80% for detecting a difference in proportions of 0.30 between the two groups (test - reference group) at a two sided p-value of 0.05.
Study 2: Urine, perineal and gut microbiome in children with BBD before and after treatment Aim and hypothesis To investigate the urine, perineal and gut microbiome in children with BBD before and after treatment.
The hypothesis of the investigators is that
1. Response to treatment can be predicted by the composition of the urine, perineal and gut microbiome in children with BBD.
2. The composition of the urine, perineal and gut microbiome is different in BBD children with recurrent UTI's compared to BBD children without recurrent UTI's.
3. The urine, perineal and gut microbiome in children with BBD will change when bladder and bowel symptoms successfully treated.
Materials and methods
The study is a multicentre study consisting of two elements:
1. a cohort study to investigate, whether the urine, perineal and gut microbiome can predict response to treatment and whether it changes during treatment period
2. a case control study to investigate whether the urine, perineal and gut microbiome is different in children with BBD and recurrent UTI 's and children with BBD without recurrent UTI 's.
The study population consists of children with BBD included in study 1.
Collection and analysis of samples A urine-, stool sample and a perineum swab will be collected from all participants before initiation of treatment and after 3 months of treatment as described in study 1. Bacterial DNA will be extracted and the microbiome will be determined.
Data storage Biological material will be pseudonymised and stored in a -80 degree fridge until analysis is performed.
Statistical analysis for all 3 studies Distribution and variance will be analysed by QQ plot, Shapiro-Wilks test and Bartletts test. Microbiota alpha-diversity will be addressed by ASV richness, Faith's phylogenetic diversity, Shannon diversity index, and Pielou's evenness index. Beta-diversity analysis will include principal coordinate analysis (PCoA) using Bray-Curtis dissimilarity, weighted and unweighted UniFrac. Parametric data will be compared using Student's t-test or one-way ANOVA and Tukey´s post hoc test, while non-parametric data will be compared with Kruskal-Wallis test or Mann-Whitney U-test. Chi Squared test will be used for proportions. Level of significance will be as following \*: p \<0.05, \*\*: p\<0.01 and \*\*\*: p\<0.001.
Ethics The studies will be conducted in accordance with the Declaration of Helsinki. All side effects will be handled in accordance with the actual legislation. No risk or unknown side effects are expected to urotherapy or medical treatment of bowel symptoms. No risk, side effects or discomfort is expected from collection of urine, stool and perineum samples or from uroflowmetry or transabdominal ultrasound.
Perspectives BBD is a common condition in childhood. It is associated with a considerable psychological burden and a risk of more severe physical complications.
The term BBD is recently defined and therefore only sparsely investigated. The studies will provide basic knowledge about characteristics of the BBD patients and contribute new information about the optimal treatment of BBD children.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Bladder and Bowel Dysfunction
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment of constipation and/or faecal incontinence
Medical treatment of bowel symptoms in accordance with the guidelines of The European Society for Paediatric Gastroenterology, Hepatology and Nutrition
Group Type
ACTIVE_COMPARATOR
Polyethylene Glycol 3350
Intervention Type
DRUG
PEG3350, klysma, laxoberal and magnesia will be administered in accordance with actual guidelines for treatment of constipation in children
Treatment of constipation and/or faecal incontinence combined with urotherapy
Medical treatment of bowel symptoms in accordance with the guidelines of The European Society for Paediatric Gastroenterology, Hepatology and Nutrition combined with standard urotherapy in accordance with International Children's Continence Society (ICCS)
Group Type
ACTIVE_COMPARATOR
Polyethylene Glycol 3350
Intervention Type
DRUG
PEG3350, klysma, laxoberal and magnesia will be administered in accordance with actual guidelines for treatment of constipation in children
Urotherapy
Intervention Type
BEHAVIORAL
Information and demystification of the disorder along with behavioural modification such as timed voiding, proper voiding posture, avoidance of holding manoeuvers and balanced fluid intake
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Polyethylene Glycol 3350
PEG3350, klysma, laxoberal and magnesia will be administered in accordance with actual guidelines for treatment of constipation in children
Intervention Type
DRUG
Urotherapy
Information and demystification of the disorder along with behavioural modification such as timed voiding, proper voiding posture, avoidance of holding manoeuvers and balanced fluid intake
Intervention Type
BEHAVIORAL
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Magnesia
Laxoberal
Glyoktylklysma
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 5-14 years and 9 months at time of inclusion
* Diagnosed with urinary incontinence and/or enuresis nocturna defined by the ICCS criteria
* Diagnosed with constipation and/or faecal incontinence defined by the ROME IV criteria
* Normal clinical examination
* Parents/guardian can understand the written and spoken information
* Informed assent to participation from both parents/guardian
* Diagnosed with urinary incontinence and/or enuresis nocturna defined by the ICCS criteria
* Diagnosed with constipation and/or faecal incontinence defined by the ROME IV criteria
* Normal clinical examination
* Parents/guardian can understand the written and spoken information
* Informed assent to participation from both parents/guardian
Exclusion Criteria
* Neuropathic or anatomical abnormalities in the urinary tract or gastrointestinal canal
* Earlier surgical intervention of the urinary tract (except circumcision)
* Neurological illness or earlier cerebral surgical intervention
* On-going urinary tract infection
* On-going treatment with anticholinergics and/or β3-adenoceptoragonist
* On-going treatment with laxatives in correct dosage (PEG3350 1-2 g/kg/day)
* Inflammatory bowel disease
* Other disorder affection bladder or bowel function
* For Study 2 (microbiome): Systemic antibiotics within the past 3 months
* Earlier surgical intervention of the urinary tract (except circumcision)
* Neurological illness or earlier cerebral surgical intervention
* On-going urinary tract infection
* On-going treatment with anticholinergics and/or β3-adenoceptoragonist
* On-going treatment with laxatives in correct dosage (PEG3350 1-2 g/kg/day)
* Inflammatory bowel disease
* Other disorder affection bladder or bowel function
* For Study 2 (microbiome): Systemic antibiotics within the past 3 months
Minimum Eligible Age
5 Years
Maximum Eligible Age
15 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sofie Axelgaard, MD
Role: STUDY_CHAIR
Department of Childhood and Adolescent Medicine, Regional Hospital Goedstrup
Soeren Hagstroem, Professor, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Childhood and Adolescent Medicine, Aalborg University Hospital
Luise Borch, MD, PhD
Role: STUDY_DIRECTOR
Department of Childhood and Adolescent Medicine, Regional Hospital Goedstrup
Konstantinos Kamperis, MD, PhD
Role: STUDY_DIRECTOR
Department of Childhood and Adolescent Medicine, Aarhus University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aalborg University Hospital
Aalborg, , Denmark
Site Status
NOT_YET_RECRUITING
Aarhus University Hospital
Aarhus, , Denmark
Site Status
RECRUITING
Goedstrup Regional Hospital
Herning, , Denmark
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Denmark
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Conway PH, Cnaan A, Zaoutis T, Henry BV, Grundmeier RW, Keren R. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA. 2007 Jul 11;298(2):179-86. doi: 10.1001/jama.298.2.179.
Reference Type
BACKGROUND
Aguiar LM, Franco I. Bladder Bowel Dysfunction. Urol Clin North Am. 2018 Nov;45(4):633-640. doi: 10.1016/j.ucl.2018.06.010. Epub 2018 Sep 7.
Reference Type
BACKGROUND
Shaikh N, Hoberman A, Wise B, Kurs-Lasky M, Kearney D, Naylor S, Haralam MA, Colborn DK, Docimo SG. Dysfunctional elimination syndrome: is it related to urinary tract infection or vesicoureteral reflux diagnosed early in life? Pediatrics. 2003 Nov;112(5):1134-7. doi: 10.1542/peds.112.5.1134.
Reference Type
BACKGROUND
Dos Santos J, Varghese A, Koyle M. Recommendations for the management of bladder bowel dysfunction in children. Pediatr Therapeut, 2014;4:1.
Reference Type
BACKGROUND
Halachmi S, Farhat WA. Interactions of constipation, dysfunctional elimination syndrome, and vesicoureteral reflux. Adv Urol. 2008;2008:828275. doi: 10.1155/2008/828275.
Reference Type
BACKGROUND
Kaplan SA, Dmochowski R, Cash BD, Kopp ZS, Berriman SJ, Khullar V. Systematic review of the relationship between bladder and bowel function: implications for patient management. Int J Clin Pract. 2013 Mar;67(3):205-16. doi: 10.1111/ijcp.12028.
Reference Type
BACKGROUND
Koff SA, Wagner TT, Jayanthi VR. The relationship among dysfunctional elimination syndromes, primary vesicoureteral reflux and urinary tract infections in children. J Urol. 1998 Sep;160(3 Pt 2):1019-22. doi: 10.1097/00005392-199809020-00014.
Reference Type
BACKGROUND
Chase JW, Homsy Y, Siggaard C, Sit F, Bower WF. Functional constipation in children. J Urol. 2004 Jun;171(6 Pt 2):2641-3. doi: 10.1097/01.ju.0000109743.12526.42.
Reference Type
BACKGROUND
Erickson BA, Austin JC, Cooper CS, Boyt MA. Polyethylene glycol 3350 for constipation in children with dysfunctional elimination. J Urol. 2003 Oct;170(4 Pt 2):1518-20. doi: 10.1097/01.ju.0000083730.70185.75.
Reference Type
BACKGROUND
Borch L, Hagstroem S, Bower WF, Siggaard Rittig C, Rittig S. Bladder and bowel dysfunction and the resolution of urinary incontinence with successful management of bowel symptoms in children. Acta Paediatr. 2013 May;102(5):e215-20. doi: 10.1111/apa.12158. Epub 2013 Feb 11.
Reference Type
BACKGROUND
Hoebeke P, Bower W, Combs A, De Jong T, Yang S. Diagnostic evaluation of children with daytime incontinence. J Urol. 2010 Feb;183(2):699-703. doi: 10.1016/j.juro.2009.10.038. Epub 2009 Dec 21.
Reference Type
BACKGROUND
Loening-Baucke V. Urinary incontinence and urinary tract infection and their resolution with treatment of chronic constipation of childhood. Pediatrics. 1997 Aug;100(2 Pt 1):228-32. doi: 10.1542/peds.100.2.228.
Reference Type
BACKGROUND
Hagstroem S, Rittig N, Kamperis K, Mikkelsen MM, Rittig S, Djurhuus JC. Treatment outcome of day-time urinary incontinence in children. Scand J Urol Nephrol. 2008;42(6):528-33. doi: 10.1080/00365590802098367.
Reference Type
BACKGROUND
Mulders MM, Cobussen-Boekhorst H, de Gier RP, Feitz WF, Kortmann BB. Urotherapy in children: quantitative measurements of daytime urinary incontinence before and after treatment according to the new definitions of the International Children's Continence Society. J Pediatr Urol. 2011 Apr;7(2):213-8. doi: 10.1016/j.jpurol.2010.03.010. Epub 2010 Jun 11.
Reference Type
BACKGROUND
Keren R, Shaikh N, Pohl H, Gravens-Mueller L, Ivanova A, Zaoutis L, Patel M, deBerardinis R, Parker A, Bhatnagar S, Haralam MA, Pope M, Kearney D, Sprague B, Barrera R, Viteri B, Egigueron M, Shah N, Hoberman A. Risk Factors for Recurrent Urinary Tract Infection and Renal Scarring. Pediatrics. 2015 Jul;136(1):e13-21. doi: 10.1542/peds.2015-0409. Epub 2015 Jun 8.
Reference Type
BACKGROUND
Patzer L, Seeman T, Luck C, Wuhl E, Janda J, Misselwitz J. Day- and night-time blood pressure elevation in children with higher grades of renal scarring. J Pediatr. 2003 Feb;142(2):117-22. doi: 10.1067/mpd.2003.13.
Reference Type
BACKGROUND
Bower WF. Self-reported effect of childhood incontinence on quality of life. J Wound Ostomy Continence Nurs. 2008 Nov-Dec;35(6):617-21. doi: 10.1097/01.WON.0000341476.71685.78.
Reference Type
BACKGROUND
Equit M, Hill J, Hubner A, von Gontard A. Health-related quality of life and treatment effects on children with functional incontinence, and their parents. J Pediatr Urol. 2014 Oct;10(5):922-8. doi: 10.1016/j.jpurol.2014.03.002. Epub 2014 Mar 26.
Reference Type
BACKGROUND
Whiteside SA, Razvi H, Dave S, Reid G, Burton JP. The microbiome of the urinary tract--a role beyond infection. Nat Rev Urol. 2015 Feb;12(2):81-90. doi: 10.1038/nrurol.2014.361. Epub 2015 Jan 20.
Reference Type
BACKGROUND
Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018 Feb;11(1):1-10. doi: 10.1007/s12328-017-0813-5. Epub 2017 Dec 29.
Reference Type
BACKGROUND
de Moraes JG, Motta ME, Beltrao MF, Salviano TL, da Silva GA. Fecal Microbiota and Diet of Children with Chronic Constipation. Int J Pediatr. 2016;2016:6787269. doi: 10.1155/2016/6787269. Epub 2016 Jun 23.
Reference Type
BACKGROUND
Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol. 2014 Jul;16(7):1024-33. doi: 10.1111/cmi.12308. Epub 2014 Jun 2.
Reference Type
BACKGROUND
Pearce MM, Hilt EE, Rosenfeld AB, Zilliox MJ, Thomas-White K, Fok C, Kliethermes S, Schreckenberger PC, Brubaker L, Gai X, Wolfe AJ. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. mBio. 2014 Jul 8;5(4):e01283-14. doi: 10.1128/mBio.01283-14.
Reference Type
BACKGROUND
Jung C, Brubaker L. The etiology and management of recurrent urinary tract infections in postmenopausal women. Climacteric. 2019 Jun;22(3):242-249. doi: 10.1080/13697137.2018.1551871. Epub 2019 Jan 9.
Reference Type
BACKGROUND
Kinneman L, Zhu W, Wong WSW, Clemency N, Provenzano M, Vilboux T, Jane't K, Seo-Mayer P, Levorson R, Kou M, Ascher D, Niederhuber JE, Hourigan SK. Assessment of the Urinary Microbiome in Children Younger Than 48 Months. Pediatr Infect Dis J. 2020 Jul;39(7):565-570. doi: 10.1097/INF.0000000000002622.
Reference Type
BACKGROUND
Kassiri B, Shrestha E, Kasprenski M, Antonescu C, Florea LD, Sfanos KS, Wang MH. A Prospective Study of the Urinary and Gastrointestinal Microbiome in Prepubertal Males. Urology. 2019 Sep;131:204-210. doi: 10.1016/j.urology.2019.05.031. Epub 2019 Jun 10.
Reference Type
BACKGROUND
Levy EI, Lemmens R, Vandenplas Y, Devreker T. Functional constipation in children: challenges and solutions. Pediatric Health Med Ther. 2017 Mar 9;8:19-27. doi: 10.2147/PHMT.S110940. eCollection 2017.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BBD_Children
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities
NCT07059858
RECRUITING
Prevalence, Etiology and Therapy of Micturition Disorders of Children With a Mental and/or Motoric Disability
NCT00148005
COMPLETED
NA
Video Game-Based Balance Training in Children With Lower Urinary Tract Dysfunction
NCT07126977
RECRUITING
NA
Brain Activity Among Children With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children
NCT05989646
UNKNOWN
NA
Programmable Timer in the Bladder Rehabilitation Treatment of OAB
NCT00238680
COMPLETED
NA
Connective Tissue Manipulation on Pelvic Floor Muscle Functions in Children
NCT05824429
COMPLETED
NA
Pelvic Floor Muscle Activity, Respiratory Functions, Respiratory Muscle Strength, and Functional Capacity in Children With Lower Urinary Tract Dysfunction
NCT06652178
COMPLETED
Parent Education and Medical Play: A Comparison of Psychological Preparation Strategies for Voiding Cystourethrogram
NCT01578291
TERMINATED
NA
Clinical and Urodynamic Evaluation of Surgical Repair of Pelvic Organ Prolapse Associated With Lower Urinary Tract Symptoms
NCT04793126
COMPLETED
PHASE2
Effects of Lumbopelvic Massage and Exercise Training in Children With Lower Urinary Tract Dysfunction
NCT06251557
NOT_YET_RECRUITING
NA
Urotherapy vs. Urotherapy With Constipation Treatment for Nocturnal Enuresis
NCT02337413
WITHDRAWN
PHASE4
Relationship Between Pelvic Angle, Femoral Anteversion, and Hip Muscle Strength Ratios in Bladder-bowel Dysfunction
NCT05182671
COMPLETED
Diaphragmatic Breathing Exercises and Pelvic Floor Retraining in Children With Dysfunctional Voiding
NCT04981340
UNKNOWN
NA
Examining the Relationship Between Core Muscles and Bladder Issues in Children
NCT06317116
ENROLLING_BY_INVITATION
Prevalence of Detrusor Underactivity and Bladder Outlet Obstruction in Female Without Cystocele
NCT04184752
COMPLETED
Respiratory and Pelvic Floor Muscle Functions of Children With Lower Urinary Tract Dysfunction
NCT06728540
COMPLETED
NA
Investigation of the Effectiveness of Different Interventions for Lower Urinary Tract Symptoms
NCT06399887
COMPLETED
NA
Non-invasive Sacral Nerve Stimulation in Children and Adolescents With Chronic Constipation
NCT04710433
COMPLETED
NA
Impact, Feasibility, and Acceptability of Bladder Basics
NCT05852353
COMPLETED
NA
Reformer Pilates Exerises in Bladder and Bowel Dysfunction
NCT05779709
COMPLETED
NA
Linguistic Validation of the Childhood Bladder and Bowel Dysfunction Questionnaire (CBBDQ) for 5-12 Years Old in Korean
NCT04490642
UNKNOWN
New Generation Rehabilitation Approach in Children With Dysfunctional Voiding
NCT06743165
RECRUITING
NA
Safety and Performance of UCon for the Treatment of the Symptoms of Overactive Bladder (OAB) / Bowel Dysfunction (BD)
NCT05368246
COMPLETED
NA
Posterior Tibial Nerve Stimulation for Children With Pelvic Floor Dyssynergia
NCT06528470
RECRUITING
NA